Immunovant's Batoclimab Fails to Meet Primary Endpoint in Phase 3 Thyroid Eye Disease Trials

Immunovant reported that two Phase 3 studies of batoclimab in thyroid eye disease failed to meet their primary endpoint. However, patients showed greater proptosis improvement from baseline after the initial high-dose period than the following low-dose period. Safety results were consistent with previous findings, and the company remains focused on advancing IMVT-1402 in multiple indications.